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Abstract
Background: Although stereotactic radiotherapy (SRT) for vestibular schwannoma has demonstrated excellent local
control rates, hearing deterioration is often reported after treatment. We therefore wished to assess the change in
hearing loss after SRT and to determine which patient, tumor and treatment-related factors influence deterioration.
Methods: We retrospectively analyzed progression of hearing loss in patients with vestibular schwannoma who
had received stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) as a primary treatment
between 2000 and 2014. SRS had been delivered as a single fraction of 12 Gy, and patients treated with FSRT had
received 30 fractions of 1.8 Gy. To compare the effects of SRS and FSRT, we converted cochlear doses into EQD2.
Primary outcomes were loss of functional hearing, Gardner Robertson (GR) classes I and II, and loss of baseline
hearing class. These events were used in Kaplan Meier plots and Cox regression. We also calculated the rate of change
in Pure Tone Average (PTA) in dB per month elapsed after radiation—a measure we use in linear regression—to assess
the associations between the rate of change in PTA and age, pre-treatment hearing level, tumor size, dose scheme,
cochlear dose, and time elapsed after treatment (time-to-first-audiogram).
Results: The median follow-up was 36months for 67 SRS patients and 63months for 27 FSRT patients. Multivariate
Cox regression and in linear regression both showed that the cochlear V90 was significantly associated with the
progression of hearing loss. But although pre-treatment PTA correlated with rate of change in Cox regression, it
did not correlate in linear regression. The time-to-first-audiogram was also significantly associated, indicating time
dependency of the rate of change. None of the analysis showed a significant difference between dose schemes.
Conclusions: We found no significant difference between SRS and FSRT. As the deterioration in hearing after
radiotherapy for vestibular schwannoma was associated with the cochlea V90, restricting the V90 may reduce
progression of hearing loss. The association between loss of functional hearing and baseline PTA seems to be
biased by the use of a categorized variable for hearing loss.
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Background
An increasing number of studies have shown excellent
local control after stereotactic radiotherapy (SRT) for
vestibular schwannoma. [1–3]. There are two modalities
for delivering SRT: single-fraction stereotactic radiosurgery
(SRS) and fractionated stereotactic radiotherapy (FSRT).
As both have been reported to lead to local control rates in
the range of 93–100%, the focus has now shifted towards
reducing toxicity.
While progression of hearing loss is often reported after
SRT [4–9], there is no consensus on the factors that influ-
ence hearing outcome. Several papers [10–12], but not all
[13], have reported that hearing outcome is significantly
associated with age, tumor size and pre-treatment hearing
level. Little is known about the influence of cochlear dose
on hearing deterioration. Although most studies have not
found a significant association between maximum coch-
lear dose and hearing deterioration [11, 14, 15], some have
reported that hearing deterioration was significantly asso-
ciated with mean cochlear dose [11, 14]; with the volume
of the cochlea receiving at least 90% of the prescribed dose
(V90) [8]; or with the volume of the cochlea receiving at
least 5.3 Gy in a single dose [12].
Another area of uncertainty is whether FSRT yields
better hearing preservation rates than SRS. A recent
systematic review of clinical trials concluded that the
evidence for better hearing preservation in vestibular
schwannoma patients treated with FSRT is inconclusive
[3]. This may be due to the lack of randomized trials
comparing the two dose schemes. The only study that
tried to address this issue in a randomized setting was
closed prematurely and was modified into an observational
study [16]. While it reported better hearing preservation
after FSRT, it did not perform a cochlear DVH analysis.
Neither did it have sufficient potential control for known
baseline factors such as NF2 and tumor size. However,
many other studies have not reported a significant
difference [5, 6, 17, 18].
Many studies have analyzed hearing loss with a time-to-
event analysis, using the preservation of functional hearing
or preservation of the baseline hearing class as outcome
variable. The hearing classifications used most commonly
are the Gardner Robertson (GR) classification, and the clas-
sification of the American Academy of Otolaryngology –
Head and Neck Surgery (AAO-HNS). Patients retaining
GR class I or II, which correspond to AAO-HNS classes A
or B, are considered to have preserved functional hearing.
The reported rates of long-term functional hearing preser-
vation after irradiation differ widely, from 31 to 94% [4].
Although the term functional hearing is an attractive
concept, the limits of audiological functioning are not well
defined by the limits of GR class I and II. Even when hear-
ing loss exceeds 50 dB hearing may still be serviceable in
the presence of good speech perception, but a drop in
speech discrimination below 70% impedes audiological
function at any level of pure tone average (PTA).
As better identification of factors that influence hearing
loss would help physicians to optimize treatment planning
and to achieve better hearing outcomes, we wished to
identify factors that influence the rate of change in hearing
after SRT. Hypothesizing that associations predicting the
change in hearing after SRT might be identified through
the use of continuous variables such as PTA rather than a
dichotomous variable such as functional hearing classes,
we used the change in PTA over time in our analysis,
alongside the time-to-event analysis to analyze preserva-
tion of functional hearing class and preservation of GR
baseline class.
Methods and materials
Study aim
The purpose of our study was to assess the change in hear-
ing after SRS and FSRT in vestibular schwannoma patients,
and to investigate patient, tumor, and treatment-related
factors that influence hearing loss.
Study design
This study was performed as a retrospective, single-in-
stitution study. The study protocol was approved by
our local Medical Ethics Review Board.
Patient enrollment
We reviewed all patients with unilateral vestibular schwan-
noma who had been treated with stereotactic radiotherapy
at the Department of Radiation Oncology at Erasmus
University Hospital between 1 January 2000 and 31
December 2014. The diagnosis of vestibular schwannoma
had been based on the clinical presentation and the typical
radiological appearance of a cerebellopontine angle (CPA)
tumor upon gadolinium-enhanced magnetic resonance
imaging (MRI). We excluded the following patients:
those who had had previous interventions for vestibular
schwannoma, those with neurofibromatosis type 2, and
those who had not been audiometrically assessed less
than 6 months before treatment. Unlike many other
studies, we included all patients who had had measurable
hearing before treatment; this enabled us to investigate the
effect of treatment irrespective of pre-treatment hearing.
We defined measurable hearing as PTA ≤ 100 dB and
Speech Discrimination Score (SDS) > 0%, which corre-
sponds to GR classes 1 through 4. Ninety-four patients
of the 225 who had been treated were eligible for
inclusion.
Treatment allocation
All patients had been discussed in a multidisciplinary
tumor board attended by a radiation oncologist, a
neurosurgeon, an otolaryngologist and a specialized nurse
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practitioner. Treatment with SRT had been recommended
for tumors touching or displacing the brain stem or cere-
bellar peduncle, and for tumors that progressed during
wait and scan policy. The choice of technique had then
been based on tumor size. Tumors extending up to 3 cm
in the CPA cistern were preferably treated with SRS,
whereas larger tumors were treated with FSRT. In the
early years of the study period, FSRT was preferred to
SRS for patients with functional hearing, independent
of tumor size. Later on, this practice was abandoned on
the basis of new publications [5, 6, 18], which did not
find that FRST led to confirm a better hearing result of
FSRT. In the event of symptoms due to trigeminal
nerve or brain stem compression, a surgical intervention
was recommended.
Audiometry
Pure tone and speech audiometry had been performed
in all patients less than 6 months before treatment and
up to 10 years after its completion. We calculated PTA
on the basis of the masked bone conduction responses
at 500, 1000, 2000 and 4000 Hz. As the maximum
phoneme score of “Consonant Vowel Consonant” words
in percentages had been used for the SDS, we then
classified according to the GR hearing classification
[19]. GR hearing classes I and II represent functional
hearing.
Radiotherapy technique
During treatment, patients receiving SRS had been
were immobilized using the invasive Brown-Roberts-Wells
frame (Radionics, Integra NeuroSciences, Burlington,
Massachusetts, USA), and with the relocatable Gill-
Thomas-Cosman frame (Radionics) for FSRT. Until March
2014, treatments were delivered with a conventional LINAC
(Varian 2300 CD, Varian Medical Systems, Palo Alto,
California, USA) using 6 MV photons. From March 2014
onwards, SRS treatments were delivered with Cyberknife
(Accuray Inc., Sunnyvale, California, USA) using a thermo-
plastic mask for immobilisation.
Using the immobilization system, a computerized tom-
ography (CT) planning scan was acquired. These images
were fused with MRI and this dataset was used for
target delineation. The planning target volume (PTV)
was defined as the area of contrast enhancement on
T1-weighted MRI with no margin for SRS and with 2
mm margin for FSRT. The organs at risk considered
were cochlea, brainstem, trigeminal nerve, optic nerves,
optic chiasm, pituitary gland, and eyes. The cochlea
was delineated on CT. The method of delineation was
discussed with a neuroradiologist. All delineations were
performed and reviewed by two of the authors (NH,
AMR). For single-dose treatments, a dose of 12 Gy was
prescribed at the 80% isodose surrounding the PTV.
For fractionated treatments, a dose of 54 Gy was pre-
scribed at the 100% isodose with the 95% isodose sur-
rounding the PTV. FSRT was delivered in 30 daily
fractions of 1.8 Gy over a period of 6 weeks.
Follow-up
After treatment, patients were followed with MRI, audi-
ometry and clinical evaluation. A post-treatment MRI and
audiogram after SRT were planned at 12months and
thereafter at 2, 3, 5, 7 and 10 years. Not all patients com-
plied with the full follow-up schedule.
Outcome measures and variables
In the current study, our primary outcome was the pro-
gression of hearing loss after treatment. We compared
three different ways to define hearing deterioration. First,
deterioration was defined in the usual way, as loss of
functional hearing (baseline GR classes I or II). Next, it
was defined as loss of the baseline GR hearing class
(class GR I to IV). In our third analysis, hearing loss
was not categorized, but progression was measured as
the rate of change in PTA in dB per month. This rate
was calculated by dividing the difference between the
PTA of the pre-treatment audiogram and each post-
treatment audiogram by the number of months that
had elapsed since SRT.
We evaluated the relationship between progression of
hearing loss with patient, tumor, and treatment-related
factors: age, pre-treatment hearing level, tumor volume,
tumor diameter in the CPA, fractionation scheme, and
cochlear doses.
To compare SRS and FSRT, we use the linear quadratic
formula to convert cochlear doses into equivalent 2-Gy-
fraction doses (EQD2) [11]:
EQD2 ¼ D
d þ α=βð Þ
2þ α=βð Þ ð1Þ
where EQD2 is the dose in 2-Gy-fractions that is bio-
logically equivalent to the total dose D that was actually
administered in fractions of d Gy [20]. The α/β ratio is
a measure of cell death and cell repair, and can be
assessed. For the cochlea, we used an α/β ratio of 2
[11]. We measured the maximum and mean cochlear
dose. To calculate the volume of cochlea that had received
at least 90% of the prescribed dose (V90) we converted
90% of the FSRT prescribed dose to an EQD2. Next, we
sought to establish the equivalent dose delivered with
SRS. We could then calculate the volume of the cochlea
that had received this EQD2 in both the FSRT and SRS
treatments.
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Data analysis
One-way ANOVA analysis was used to evaluate the
differences between the FSRT and the SRS populations.
The relationship between the change in PTA and the
change in SDS was tested with the Wilcoxon Signed
Rank test.
After categorizing hearing according to the Gardener
Robertson grading, we used the Kaplan Meier method to
assess the preservation of useful hearing and the preser-
vation of baseline hearing class. Factors that could be
predictive of an increase in GR class were evaluated with
the Cox proportional hazard model for univariate and
multivariate analysis.
The change in PTA is a continuous outcome measure
that allows univariate and multivariate linear regression
analysis of the monthly rate of PTA increase. We used
the step-backward method to optimize both multivariate
models, this method removes factors from the model
that are not significant, until only significant factors remain.
The factors removed are rated non-significant, without
reporting a hazard ratio (HR), regression coefficient
(RC) or p-value. Relationships with p < 0.05 were con-
sidered to be significant.
We performed all analyses using the statistical pro-
grams R (version 2.13.0) and IBM SPSS (version 23).
Results
Patient characteristics
Between 01 January 2000 and 31 December 2014, 225
patients had been treated for vestibular schwannoma
with either technique. Ninety-four patients fulfilled the
criteria for inclusion in this study. Patients were excluded
due to the absence of an audiometric assessment taken
less than 6months before treatment or due to a pre-treat-
ment speech-discrimination score equal to zero.
Sixty-seven patients had been treated with SRS and 27
with FSRT. Our treatment algorithm caused differences
between the two groups (Table 1). Patients who had
been treated with SRS were older, had been in a higher
pre-treatment GR class, and had had smaller tumors.
Median follow-up had been 36months for the SRS
group and 63months for the FSRT group. None of the
patients had required an additional intervention for ves-
tibular schwannoma.
Pre-treatment hearing
Figure 1 shows the scattergram of pre-treatment hearing
levels. The PTA and SDS are significantly correlated
(r = − 0.752, p < 0.0001).
Categorization of hearing according to the Gardner
Robertson classification showed that the patients’ distri-
butions over the hearing classes differed between dose
schemes. Table 1 shows that 48.1% of FSRT patients had
started out in hearing class I and that 25.9% had started in
hearing class II. By contrast, while only 10.4% of those in
the SRS group had started out in hearing class I, 44.8%
had started in hearing class II.
Loss of functional hearing
Before radiotherapy, 57 out of 94 patient had had hearing
class I or II. Preservation of GR hearing class I or II had
not differed significantly between the two treatment
groups (Fig. 2, Table 2). One year after treatment, 84%
of the SRS patients and 71% of the FSRT patients had
preservation of useful hearing. At 3 years, useful hearing
had been retained in 27% of the SRS patients and 50% of
the FSRT patients.
Univariate Cox regression showed that loss of func-
tional hearing was significantly associated with the V90,
pre-treatment PTA, and age. After multivariate regres-
sion, pre-treatment PTA and V90 remained significant
factors.
Loss of baseline GR class
Preservation of baseline GR class did not differ signifi-
cantly between the two treatment groups (Fig. 3, and
Table 3). At 1 year after treatment, baseline GR class had
been preserved in 88% of the SRS patients and 63% of
the FSRT patients. At 3 years, it had been retained in
respectively 43 and 39%.
Univariate Cox regression showed a significant association
of loss between baseline GR hearing class and the V90.
Pre-treatment PTA was significantly associated with loss of
baseline hearing class only after multivariate regression. Age
did not show an association.
PTA increase per month
Figure 4 shows the differences per patient and per
follow-up audiogram between pre-treatment PTA and
post-treatment PTA. This shows that hearing loss con-
tinued to increase up to 90 months, so hearing did not
stabilize within this period. Figure 5 shows the monthly
rate of hearing deterioration after treatment. While PTA
had initially increased steeply in patients with an early
audiogram, audiograms after longer intervals showed a
smaller change per time unit, proportional to the time
elapsed.
To compare results between patients despite the dif-
ferent follow-up times, we included the time elapsed
after treatment as a variable in the analysis. This was
useful, as the follow-up schedule had not been adhered
to for all patients. As the greatest change occurred shortly
after treatment, we only included patients whose first
audiogram had been taken within 2 years of follow up. As
the date of audiometry clustered around the scheduled
follow-up dates, we used 21months as our cut-off for
inclusion in this analysis, i.e., between the 18-month
and 24-month follow up. Seventy-seven patients had
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had an audiometric assessment within the first 21months
(Table 4); up to the first audiogram, the mean PTA in-
crease had been 1.74 dB per month. Both the univariate
and multivariate analysis showed the PTA increase per
month to be significantly associated with age, time-to-
first-audiogram and V90(insert Table 4).
Discussion
After stereotactic irradiation for vestibular schwannoma,
hearing had deteriorated markedly. FSRT and SRS did
not differ significantly with regard to the preservation of
functional hearing and baseline GR class. The cochlear
V90 was significantly associated with hearing deterioration.
Within GR classes I & II, patients with a better PTA
remained in their hearing class for longer than patients
whose hearing had already diminished. This was not dupli-
cated in the linear regression analysis.
Method of analyzing hearing loss
Although preservation of functional hearing is a common
criterion in the analysis of hearing change in vestibular
schwannoma treatment, it has inherent limitations.
First, whereas the concept of “preservation” suggests a
stable final outcome, we found—as Fig. 4 shows—that
hearing had continued to decrease. After 2 years of
follow-up, the findings of Yomo et al. were similar: an
ongoing annual loss of 1.8 dB [21]. Second, “functional
hearing” is not adequately defined by GR classes I and
II, as speech discrimination of over 80% is needed to
understand spoken language. Limiting the analysis to pa-
tients in GR classes I and II therefore has two limitations:
Table 1 Patient, tumor and treatment characteristics
SRS group (67 patients) FSRT group (27 patients) ANOVA
p-valueN (%) mean/ median range N (%) mean/ median range
Patients
Age 67 58/59 34–80 27 48/51 27–79 < 0.001
Gender 0.2
Male 32 9
Female 35 18
Hearing
GR baseline class 0.01
1 7 (10,4) 13 (48.1)
2 30 (44.8) 7 (25.9)
3 28 (41.8) 5 (18.5)
4 2 (2.9) 2 (7.4)
Δ PTA (dB/month) 1.35/0.95 −0.86-11.13 2.9/1.65 −0.65-28 0.05
PTA pre-treatment (dB) 48.2/46.3 1.3–96 36/34 3.7–94 0.02
SDS pre-treatment (%) 78/85 18–100 83/94 3–100 0.38
Tumors
Tumor side
Left 37 14 0.8
Right 30 13
Tumor volume Pre-treatment (ml) 3.0/2.36 0.37–12.82 7.4/6.8 0.24–20.1 0.003
Tumor diameter CPA (cm) 1.7/1.56 0.64/3.34 2.4/2.56 0.67/4.22 < 0.001
Tumor diameter IAC (cm) 0.88/0.93 0.15/1.39 0.83/0.93 0/1.41 0.453
Radiation
Cochlear volume (ml) 0.17/0.17 0.08–0.31 0.22/0.22 0.17–0.36 < 0.001
Max cochlear dose EQD2 3578/3990 448–6693 4623/4840 3428–5258 < 0.001
Mean cochlear dose EQD2 1054/736 114–3211 3569/3781 1355–4866 < 0.001
V90 EQD2 (mm3) 4/0 0–51 65/50 0–256 < 0.001
Follow-up time (months) 37/36 4.8–121 61/63 8.3–123 < 0.001
All radiation doses are given in Gy in EQD2
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it includes a number of patients in the analysis whose
hearing is no longer good enough to understand spoken
language, and it excludes patients in GR classes III whose
speech perception is sufficient for them to benefit from a
hearing aid (Fig. 1). Although this cutoff point between
serviceable and non-serviceable hearing is an arbitrary
one, any other cutoff point would also be arbitrary. Rather
than limiting this analysis to patients with GR classes I
and II hearing, we extended it to all patients with measur-
able speech perception.
At any given moment after radiation, the hearing level
depends on pre-treatment hearing and on the rate of
decline up to that time. Only the rate of decline is influ-
enced by treatment. As hearing continues to decrease,
any absolute PTA outcome in dB needs to be coupled to
the corresponding length of follow up; and a rate also
couples the amount of dB lost to a time interval. There-
fore we used a rate as outcome measure, rather than an
absolute outcome in dB. We performed longitudinal
analysis of the increase in PTA in dB per month. The
rate of hearing decline is not a novel outcome measure:
Yomo et al. used longitudinal analysis to compare the
change in PTA between pre- and post-treatment hearing
loss [21]. For our analysis of the rate of change of the
PTA, we assumed that the change in PTA would be
linear. This may be valid only for short periods after
treatment, as we found that hearing deterioration accel-
erated shortly after radiation, and then slowed. (Figs. 4
and 5). For this reason, we included only audiograms
acquired within 2 years of follow up. This ensured that we
included only the period with the greatest changes, and
also that we used a comparable interval for all patients.
Patients without an audiogram within this timeframe were
excluded from the analysis.
The multivariate analysis showed time to first audio-
gram to be significantly associated with PTA increase per
month (RC -0.37). This sustains our hypothesis that the
rate of hearing deterioration decreases over time after
treatment—a finding that is in agreement with others,
who also described a rapid decline during the initial
period after treatment (ranging from 6 to 10 months [6]
to 2 years [7]), with a more gradual decline in hearing
after that. After 2 years, the hearing level did not quite
stabilize (see Fig. 4). In their series of patients, Yomo et
al. also found a slow rate of continued decline after 2
years [21]. Further research with standardized timing of
follow-up would make it possible to analyze in greater de-
tail how hearing progresses after radiotherapy. The pro-
gression we describe here suggests that all patients should
have audiometry immediately before therapy, followed by
Fig. 1 Speech discrimination score plotted against the pure tone average for all patients before treatment. The correlation coefficient is − 0.752.
Overlay of the Gardner Robertson classification grid
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audiometry every 6 months for the first 2 years after
therapy, and then at increasing intervals.
Hearing loss and pre-treatment hearing level
The Cox analysis of functional hearing showed an associ-
ation between pre-treatment hearing class and the loss of
functional hearing. This suggests that better hearing is less
sensitive to deterioration—a common finding in patients
with pre-treatment GR class I and II [7, 9, 11, 14–16]. If,
rather than a change in hearing class, the change in PTA
per month, is used as the outcome measure, there is no
association between pre-treatment hearing and deterior-
ation of hearing level. Patients with a similar rate of
change in PTA, but with a better baseline PTA, retain
Fig. 2 Kaplan-Meier curve for preservation of functional hearing (Gardner Robertson classes I and II) for stereotactic radiosurgery (SRS) and
fractionated stereotactic radiotherapy (FSRT)
Table 2 Univariate and multivariate Cox regression of loss of functional hearing in 57 patients
GR class I&II,
n = 57
Univariate Multivariate
Hr 95% CI Lower 95% CI Upper p-value HR 95% CI Lower 95% CI Upper p-value
Age 1.03 1.005 1.06 0.017 n.s.
PTA pre treatment 1.072 1.04 1.11 < 0.001 1.081 1.045 1.118 < 0.001
Tumor diameter CPA (cm) 0.72 0.47 1.12 0.15 n.s.
Tumor diameter IAC (cm) 2.70 0.93 7.85 0.07 n.s.
Tumor Volume pre- treatment (ml) 0.94 0.86 1.03 0.17 n.s.
Dose scheme (0 = fract, 1 = rs) 2.05 1.01 4.17 0.05 n.s.
Max cochlear dose EQD2
a 1 1 1 0.99 n.s.
Mean cochlear dose EQD2
a 1 1 1 0.58 n.s.
V90 cochlea EQD2 b 1.01 1.00 1.013 0.027 1.011 1.004 1.017 0.001
Cochlear volume (ml) 1.0 0.99 1.003 0.26 n.s.
time-to-first-audiogram (after treatment) 1.0 0.95 1.04 0.85 n.s.
n.s. Not significant, 95% CI = 95% confidence interval, PTA Pure tone average
aper cGy,
bper mm3
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their baseline GR class I & II longer, and in these cases the
GR classification is relatively insensitive to changes in
hearing.
Difference between FSRT and SRS
Our finding of no significant difference between SRS
and FSRT is in agreement with the findings of several
other studies that directly compared the two treatment
modalities. These studies used various outcome measures
to evaluate hearing: preservation of GR class, preservation
of GR I or II, and patient-reported hearing function [5, 6,
17, 18]. Only Andrews et al. [16] found a significant dif-
ference, with a rate of hearing preservation that was 2.5
higher in the patients treated with FSRT, However,
Fig. 3 Kaplan-Meier curve for the preservation of Gardner Robertson class for stereotactic radiosurgery (SRS) and fractionated stereotactic
radiotherapy (FSRT)
Table 3 Univariate and multivariate Cox regression analysis of increase in baseline GR class in 94 patients (Multivariate backward
method)
Total study group Univariate analysis Multivariate analysis
n = 94 HR 95% CI Lower 95% CI Upper p-value HR Lower 95% CI Upper 95% CI p-value
Age 0.98 0.97 1.000 0.079 n.s
PTA pre- treatment 0.99 0.98 1.002 0.13 0.99 0.97 1.0 0.023
Tumor diameter CPA (cm) 1.06 0.75 1.52 0.74 n.s.
Tumor diameter IAC (cm) 1.13 0.44 2.92 0.80 n.s.
Tumor volume pre- treatment (ml) 1.02 0.95 1.09 0.63 n.s.
Dose scheme (0 = FSRT, 1 = SRS) 0.84 0.48 1.48 0.54 2.19 0.95 5.038 0.067
Max cochlear dose cGy EQD2
a 1 1 1 0.33 n.s
Mean cochlear dose cGy EQD2
a 1 1 1 0.27 n.s.
V90 cochlea EQD2
b 1.008 1.002 1.014 0.006 1.013 1.006 1.021 0.001
Cochlear volume (ml) 0.998 0.993 1.003 0.37 n.s.
Time-to-first-audiogram (after treatment) 0.98 0.96 1.001 0.07
n.s. Not significant, 95% CI 95% confidence interval, PTA Pure tone average
aper cGy,
bper mm3
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Fig. 4 Differences for all patients between pre- and post-treatment PTA for each follow-up audiogram
Fig. 5 Slope of PTA increase in dB/month for each follow-up audiogram; all patients
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Andrews used Gammaknife radiosurgery and prescribed
the treatment dose to the 50% isodose, while many other
studies used LINAC SRS and prescribed the dose to the
80 to 100% isodose. This may have influenced the dose
distribution to the cochlea and acoustic nerve, and, as a
result, may have had an impact on hearing outcome
[22]. However, he did not perform a DVH analysis.
Similar percentages of hearing preservation were found
by Coughlin et al. in their large review comparing hear-
ing preservation in Gammaknife radiosurgery and linear
accelerator technologies [23].
Hearing loss and cochlear dose
In the literature there has been considerable debate on
the influence of cochlear dose on hearing loss, and also
on the method of measuring it. Although volumetric
assessment of cochlear dose seems more relevant than a
point dose [14], Thomas et al. found a significance
between patients whose hearing had been preserved and
those in whom it had deteriorated, both in volumetric
values V90, V80, V50, and in point doses Dmax and
Dmin.
Our finding that there was no significant association
between the preservation of functional hearing and the
maximum cochlear dose is in agreement with several
other studies [11, 14, 15]. While we did find a significant
association in the univariate analysis of the mean cochlear
dose and the PTA increase per month, the cochlear V90
carried a much stronger statistical association.
After investigating the cochlear V90, Rasmussen et al. and
Thomas et al. [8, 24] both reported a significant relationship
of the cochlear V90 with loss of hearing preservation after
FSRT. We investigated whether the V90 was associated with
hearing loss in both FSRT and SRS. For the SRS patients,
the V90 was often zero. This was the consequence of the
steep dose gradient generated with this technique and the
absence of PTV margins around the tumor. In agreement
with Rasmussen, the V90 was the strongest predictor of
hearing loss. It retained significance in the multivariate ana-
lysis both in the Cox analysis and in the linear regression.
Study limitations
As not all patients had complied with the follow-up
schedule, our study has several limitations. Patients had
had their post-treatment assessments at various points
in the schedule, a problem we dealt with by using the
time to first audiogram as a variable that represented the
time dependence of hearing deterioration. The sooner
after radiation the audiogram had been taken, the faster
the rate of deterioration had been. This suggests that
normal tissue-complication modeling is needed for these
stereotactic treatments.
The groups of patients who had received FSRT and
SRS differed in several respects, such as tumor size, PTV
margin and dose distribution. The two latter factors may
influence the V90, specifically when the intracanalicular
tumor component is located close to the cochlea. As our
use of the linear-quadratic approach (EQD2 formulae) was
intended to make the different fractionation schedules
comparable between the groups, readers interpreting our
results should remember that this is just a model.
Table 4 Univariate and multivariate linear regression of deterioration of the PTA in 77 patients with audiograms within 21 months
after treatment
Cases with first audiometric
follow up < = 21mnths
n = 77
Univariate Multivariate
RC 95% CI Lower 95%CI Upper Univar
p-value
RC 95% CI Lower 95% CI Upper Multivar
p-value
Age 0.072 0.005 0.139 0.035 0.078 0.030 0.261 0.012
PTA pre- treatment 0 −0.041 0.041 0.99 n.s.
Tumor diameter CPA (cm) 0.649 −0.482 1.779 0.26 n.s.
Tumor diameter IAC (cm) 2.66 −0.064 5.38 0.06 n.s.
Tumor volume pre- treatment (ml) 0.21 0.003 0.416 0.046 n.s.
Dose scheme (0 = FSRT, 1 = SRS) −1.31 −3.09 0.461 0.145 n.s.
Max cochlear dose cGy EQD2
a 0.000 0.000 0.001 0.264 n.s.
Mean cochlear dose cGy EQD2
a 0.001 0.000 0.001 0.005 n.s.
V90 cochlea EQD2
cb 0.025 0.009 0.041 0.003 0.024 0.009 0.039 0.002
Cochlear volume (ml) −0.003 − 0.020 0.014 0.74 n.s.
Time-to-first-audiogram (after treatment) −0.365 − 0.585 − 0.145 0.001 − 0.302 − 0.508 −0.096 0.005
n.s. Not significant, 95% CI 95% confidence interval, PTA Pure tone average
Outcome variable: ΔPTA in dB/month. Multivariate backward method. 0 = reference
aper cGy,
cbper mm3
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The two groups of patients receiving FSRT and SRS
differed with regard to several factors, such as tumor size,
PTV margin and the conformality of the dose distribu-
tions. The two latter factors may influence the value
obtained for the cochlea V90, especially in tumors with an
intracanalicular component that extends until the inner
ear. By using the linear quadratic model approach (EQD2
formulae), we aimed to make the two schemes we had
applied comparable. When interpreting these results, it
should be realized that this approach has some limitations.
For large fraction doses such as 12Gy, the calculations
may be less certain than for low doses per fraction.
Another point that deserves special attention is the α/β
selected to perform the EQD2 calculations. While the
value of 2 was chosen on the basis of the published
literature, it could also be argued that 3 could be also
have been used, and that these different values may
have had some small impact on the results [25]. Last
but not least, we should point out that the calculation
of the V90 was carried out taking 90% of the prescribed
dose delivered with FSRT as a reference. This approach
was chosen because the experience published on V90
and hearing loss has been reported on FSRT. The
consequence is that although we were able to compare
results on V90 with other published series, we need to
remember that the EQD2 value corresponding to the
90% of the prescribed dose delivered with FSRT will
not represent exactly the 90% of the prescribed dose
delivered with SRS.
Conclusions
Our results confirm that hearing deteriorates after SRT
for vestibular schwannoma. In our patient population, the
most rapid decline had occurred shortly after treatment.
We found that the effects of FSRT and SRS on hearing
change had not differed significantly.
The cochlear V90 was associated with progression of
hearing loss. Restricting the V90 during radiotherapy
treatment planning may help to reduce progression of
hearing loss.
Better baseline hearing does not protect against changes
in PTA. Although a protective effect may be apparent
when hearing was evaluated dichotomously, it was not
observed when the PTA was evaluated as a continuous
variable.
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